Zealand Pharma A/S was founded in 1998 as a biopharmaceutical company focusing exclusively on the design and development of peptide-based medicines to more safely and effectively treat areas of high unmet medical need. Zealand was incorporated based on the SIP® technology – a vital scientific asset for the company and its lead compound, lixisenatide
See some of Zealand Pharma’s achievements during the past 20 years here.
Zealand would like to acknowledge the vision and dedication of its principal founding members: Lars Hellerung Christiansen and SIP® inventor Dr. Bjarne Due Larsen.
Working together with its other owners Leif Helth Jensen, Dan Buxbom, and Florian Schönharting, Zealand appointed its first management team led by CEO, Professor Dr. Eva Steiness and including:
Dr Scient John Hyttel VP Biology
MI Chem E, MA David Knott VP Medicinal Chemistry
MD, PhD Jørgen Søberg Petersen Head, Pharmacology
Cand Pharm PhD Niels Mørk Head, Bioanalysis
MD, Dr. Med.Sci. Jens Damsgaard Mikkelsen Head, Molecular Pharmacology
Cand Pharm Hanne Løve Lembøl Project Manager